Experience of Using Atezolizumab in 1st Line Therapy of Metastatic Urothelial Cancer

Onkourologiya - Russian Federation
doi 10.17650/1726-9776-2019-15-3-113-119
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Publishing House ABV Press

Related search

Application of Anti-Pd-L1 Monoclonal Antibody Atezolizumab in Second Line Therapy of Common Urothelial Bladder Cancer

Effective Pharmacotherapy
2019English

Xeloda as First-Line Therapy of Metastatic Colorectal Cancer-Our Experience

Archive of Oncology
OncologyHematology
2002English

Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2018English

Overall Survival, Costs, and Healthcare Resource Use by Line of Therapy in Medicare Patients With Newly Diagnosed Metastatic Urothelial Carcinoma

Journal of Medical Economics
Health Policy
2019English

Oral Piritrexim, an Effective Treatment for Metastatic Urothelial Cancer

British Journal of Cancer
Cancer ResearchOncology
1993English

First-Line Therapy for Metastatic Colorectal Cancer: Current Perspectives and Future Directions

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2019English

Experience of the Use of Combination of ELF in the Induction First-Line Chemotherapy for Metastatic Gastric Cancer

Malignant tumours
2017English

Third- Or Later-Line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice

Clinical Colorectal Cancer
OncologyGastroenterology
2019English

Exemestane as Third and Fourth Line Hormonal Therapy for Metastatic Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy